{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:52:45Z","timestamp":1781880765212,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Educational and Teaching Research Project Fund of Kunming Medical University","award":["Grant No. 2024-JY-Y-128"],"award-info":[{"award-number":["Grant No. 2024-JY-Y-128"]}]},{"name":"Yunnan Province College Student Innovation Training Program Project Fund","award":["Grant No. 202510678050X"],"award-info":[{"award-number":["Grant No. 202510678050X"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05019-8","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:14:55Z","timestamp":1777641295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab induced life threatening adrenal crisis in a patient with recurrent adrenocortical carcinoma after unilateral adrenalectomy"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1467-8125","authenticated-orcid":false,"given":"Benmo","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9982-5228","authenticated-orcid":false,"given":"Chengbin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0483-7045","authenticated-orcid":false,"given":"Sinan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6485-4291","authenticated-orcid":false,"given":"Weixiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guomin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingling","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duoneng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2908-4075","authenticated-orcid":false,"given":"Wei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5160-6155","authenticated-orcid":false,"given":"Libo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3836-5941","authenticated-orcid":false,"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"5019_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-242895","volume":"14","author":"DN Correia","year":"2021","unstructured":"Correia DN, Carvalho IRD, Mangi JA. Virilising adrenocortical carcinoma. BMJ Case Rep. 2021;14:e242895. https:\/\/doi.org\/10.1136\/bcr-2021-242895.","journal-title":"BMJ Case Rep"},{"key":"5019_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235901","volume":"14","author":"E Ruggiero","year":"2022","unstructured":"Ruggiero E, Tizianel I, Caccese M, et al. Advanced adrenocortical carcinoma: from symptoms control to palliative care. Cancers. 2022;14:5901. https:\/\/doi.org\/10.3390\/cancers14235901.","journal-title":"Cancers"},{"key":"5019_CR3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.71998","author":"M Costa","year":"2024","unstructured":"Costa M, Santos S, Pereira S, et al. Adrenocortical carcinoma: a challenging diagnosis. Cureus. 2024. https:\/\/doi.org\/10.7759\/cureus.71998.","journal-title":"Cureus"},{"key":"5019_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8120551","volume":"8","author":"RM Paragliola","year":"2020","unstructured":"Paragliola RM, Corsello A, Locantore P, et al. Medical approaches in adrenocortical carcinoma. Biomedicines. 2020;8:551. https:\/\/doi.org\/10.3390\/biomedicines8120551.","journal-title":"Biomedicines"},{"key":"5019_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/CCO.0000000000000695","volume":"33","author":"G De Filpo","year":"2021","unstructured":"De Filpo G, Mannelli M, Canu L. Adrenocortical carcinoma: current treatment options. Curr Opin Oncol. 2021;33:16\u201322. https:\/\/doi.org\/10.1097\/CCO.0000000000000695.","journal-title":"Curr Opin Oncol"},{"key":"5019_CR6","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s40618-020-01306-5","volume":"43","author":"EP Brabo","year":"2020","unstructured":"Brabo EP, Moraes AB, Neto LV. The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature. J Endocrinol Invest. 2020;43:1531\u201342. https:\/\/doi.org\/10.1007\/s40618-020-01306-5.","journal-title":"J Endocrinol Invest"},{"key":"5019_CR7","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/cancers16050900","volume":"16","author":"O Ababneh","year":"2024","unstructured":"Ababneh O, Ghazou A, Alawajneh M, et al. The efficacy and safety of immune checkpoint inhibitors in adrenocortical carcinoma: a systematic review and meta-analysis. Cancers. 2024;16:900. https:\/\/doi.org\/10.3390\/cancers16050900.","journal-title":"Cancers"},{"key":"5019_CR8","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.107.006","author":"B Chahla","year":"2025","unstructured":"Chahla B, Stephen B, Song J, et al. Phase 2 study of monotherapy with pembrolizumab for advanced adrenocortical carcinoma. Endocr Abstr. 2025. https:\/\/doi.org\/10.1530\/endoabs.107.006.","journal-title":"Endocr Abstr"},{"key":"5019_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000347","volume":"8","author":"A Naing","year":"2020","unstructured":"Naing A, Meric-Bernstam F, Stephen B, et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020;8:e000347. https:\/\/doi.org\/10.1136\/jitc-2019-000347.","journal-title":"J Immunother Cancer"},{"key":"5019_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4:173. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064.","journal-title":"JAMA Oncol"},{"key":"5019_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9:e002435. https:\/\/doi.org\/10.1136\/jitc-2021-002435.","journal-title":"J Immunother Cancer"},{"key":"5019_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2025.100978","volume":"44","author":"I Cherradi","year":"2025","unstructured":"Cherradi I, Ichou M, Houssaini MS, Ismaili N. Management of immune-related adverse events under PD-1\/PD-L1 inhibitors: insights from a Moroccan real-world experience. Cancer Treat Res Commun. 2025;44:100978. https:\/\/doi.org\/10.1016\/j.ctarc.2025.100978.","journal-title":"Cancer Treat Res Commun"},{"key":"5019_CR13","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-23-0296","volume":"31","author":"A Angelousi","year":"2024","unstructured":"Angelousi A, Tzoulis P, Tsoli M, et al. Immunotherapy for endocrine tumours: a clinician\u2019s perspective. Endocr Relat Cancer. 2024;31:e230296. https:\/\/doi.org\/10.1530\/ERC-23-0296.","journal-title":"Endocr Relat Cancer"},{"key":"5019_CR14","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1097\/JS9.0000000000000373","volume":"109","author":"C Sohrabi","year":"2023","unstructured":"Sohrabi C, Mathew G, Maria N, et al. The SCARE 2023 guideline: updating consensus surgical CAse REport (SCARE) guidelines. Int J Surg. 2023;109:1136\u201340. https:\/\/doi.org\/10.1097\/JS9.0000000000000373.","journal-title":"Int J Surg"},{"key":"5019_CR15","doi-asserted-by":"publisher","unstructured":"Jennings B, Arenz A, Frankki SM, Riaz A (2025) Diagnosis and management of immune checkpoint inhibitor-associated adrenal insufficiency: a single-institution experience. J Oncol Pharm Pract 10781552251332284. https:\/\/doi.org\/10.1177\/10781552251332284","DOI":"10.1177\/10781552251332284"},{"key":"5019_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1295310","volume":"14","author":"H Wei","year":"2024","unstructured":"Wei H, Zuo A, Chen J, et al. Adrenal crisis mainly manifested as recurrent syncope secondary to tislelizumab: a case report and literature review. Front Immunol. 2024;14:1295310. https:\/\/doi.org\/10.3389\/fimmu.2023.1295310.","journal-title":"Front Immunol"},{"key":"5019_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1563629","volume":"16","author":"Z Yao","year":"2025","unstructured":"Yao Z, Chen H, Hu X, et al. Delayed diagnosis of the full triad autoimmune polyendocrine syndrome type 2 with adrenal crisis: a case report and literature review. Front Immunol. 2025;16:1563629. https:\/\/doi.org\/10.3389\/fimmu.2025.1563629.","journal-title":"Front Immunol"},{"key":"5019_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245786","volume":"15","author":"A Basek","year":"2023","unstructured":"Basek A, Jakubiak GK, Cie\u015blar G, Stanek A. Life-threatening endocrinological immune-related adverse events of immune checkpoint inhibitor therapy. Cancers. 2023;15:5786. https:\/\/doi.org\/10.3390\/cancers15245786.","journal-title":"Cancers"},{"key":"5019_CR19","first-page":"203","volume":"47","author":"S Iwama","year":"2020","unstructured":"Iwama S. Endocrine dysfunction associated with immune checkpoint blockade. Gan Kagaku Ryoho. 2020;47:203\u20136.","journal-title":"Gan Kagaku Ryoho"},{"key":"5019_CR20","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714\u201368. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385.","journal-title":"J Clin Oncol"},{"key":"5019_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy\u2014immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13:195\u2013207. https:\/\/doi.org\/10.1038\/nrendo.2016.205.","journal-title":"Nat Rev Endocrinol"},{"key":"5019_CR22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1210\/jc.2015-1710","volume":"101","author":"SR Bornstein","year":"2016","unstructured":"Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:364\u201389. https:\/\/doi.org\/10.1210\/jc.2015-1710.","journal-title":"J Clin Endocrinol Metab"},{"key":"5019_CR23","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217\u201338. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001.","journal-title":"Ann Oncol"},{"key":"5019_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.981084","volume":"12","author":"D Geng","year":"2022","unstructured":"Geng D, Wang Y, Zhang X, et al. Clinical course and management of insidious adrenal crisis manifested initially as hyperpyrexia secondary to pembrolizumab: case reports and literature review. Front Oncol. 2022;12:981084. https:\/\/doi.org\/10.3389\/fonc.2022.981084.","journal-title":"Front Oncol"},{"key":"5019_CR25","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO\u2013EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1476\u201390. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2099.","journal-title":"Ann Oncol"},{"key":"5019_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1507\/endocrj.EJ16-0596","volume":"64","author":"KY Cho","year":"2017","unstructured":"Cho KY, Miyoshi H, Nakamura A, et al. Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment [letter to the editor]. Endocr J. 2017;64:235\u20136. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0596.","journal-title":"Endocr J"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05019-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05019-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05019-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:04:59Z","timestamp":1781877899000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05019-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5019"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05019-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was a retrospective analysis of a single clinical case. The study protocol was formally reviewed and approved by the Ethics Committee of Yunnan Cancer Hospital (The Third Affiliated Hospital of Kunming Medical University), which granted a formal exemption from full ethical review due to the retrospective nature of the study, minimal risk to the patient, and compliance with the principles of the 1964 Declaration of Helsinki and its later amendments, as well as national medical research guidelines. All diagnostic and therapeutic procedures performed on the patient were consistent with international clinical practice guidelines and relevant regulatory requirements. Written informed consent was obtained from the patient prior to the collection, use, and analysis of her clinical data (including medical history, laboratory results, imaging findings, and treatment records) for this case report. The patient was fully informed of the study purpose, data usage scope, and potential risks (e.g., accidental information disclosure), and voluntarily signed the consent form. A copy of the signed consent form is archived in the Department of Urology, Yunnan Cancer Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for the publication of this case report, including the patient\u2019s de-identified clinical details, imaging descriptions, laboratory data, and the simplified Patient Perspective section, was obtained from the patient. The patient confirmed that she understood the content to be published and agreed to its dissemination in the scientific literature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"923"}}